Hims Pricing History and Trajectory: What Has Changed and What to Expect

How Hims Built Its Pricing Model From the Start

Hims entered the direct-to-consumer telehealth space in 2017 with a pricing strategy borrowed from software: offer a low entry price, convert users to subscriptions, and increase prices once retention is established. The company went public via SPAC merger in January 2021 at an implied valuation near $1.6 billion, creating investor pressure to grow revenue per user.

The 2017 to 2019 Acquisition Phase

At launch, Hims offered sildenafil (generic Viagra) for as little as $1 per tablet on introductory plans. Finasteride for hair loss was priced around $20/month, well below retail pharmacy costs at the time. These prices were not sustainable margin-wise; they functioned as customer acquisition costs baked into product pricing.

The FDA's generic drug approval pipeline matters here. The FDA approved the first generic sildenafil in December 2017 under the 505(b)(2) pathway, which immediately collapsed ingredient costs for any telehealth platform willing to source compounded or generic versions. Hims and peers benefited from this directly.

The 2020 to 2022 Scale Phase

Between 2020 and 2022, Hims quietly restructured pricing tiers. The single-dose sildenafil option remained visible in marketing but required a 3-month prepay to access. Month-to-month rates for the same medication increased to $4, $6 per dose. Finasteride moved from $20/month to $30, $35/month on standard plans.

Hims & Hers Health reported $148 million in revenue for full-year 2020 and $271 million for 2021, a 83% year-over-year increase. That revenue growth was driven substantially by average order value increases, not just subscriber additions, per the company's own SEC filings.

The 2023 to 2025 Compound and GLP-1 Phase

The most significant pricing shift came with Hims adding compounded semaglutide in 2023, capitalizing on the FDA-declared shortage of Ozempic and Wegovy. Hims launched compounded semaglutide at approximately $199, $249/month, positioning it as a fraction of the $900+ brand-name Wegovy cost. The FDA maintains an active drug shortage database; semaglutide injections remained on the shortage list from mid-2022 through most of 2024.

When the FDA announced it expected the semaglutide shortage to resolve in early 2025, the regulatory status of compounded semaglutide became uncertain. Under 21 U.S.C. § 503A and 503B, compounding pharmacies may only produce copies of FDA-approved drugs during an official shortage. The resolution of that shortage threatened a core Hims revenue line. Hims responded by pivoting to "personalized" formulations with added B12 or glycine, attempting to maintain compounding eligibility, though the FDA has signaled scrutiny of this practice.

Current Pricing Across Hims Product Categories

Hims organizes products into four main verticals: sexual health, hair loss, mental health, and weight loss. Each has a distinct pricing structure and trajectory.

Sexual Health (ED Medications)

Sildenafil (generic Viagra) is the entry product. As of late 2024, Hims lists sildenafil at:

• $1/dose for a 30-dose, 3-month prepay plan (advertised "starting at")
• $3, $5/dose on a month-to-month basis
• $5, $8/dose for branded or higher-dose formulations

Tadalafil (generic Cialis, daily low-dose) runs approximately $30, $55/month depending on dose. Hims also sells a proprietary "Hard Mints" chewable sildenafil/tadalafil blend, listed at $3, $5 per dose, which commands a premium over plain generic tablets despite containing the same active ingredients at lower bioavailability certainty.

The FDA has not approved any chewable sildenafil product. Unapproved drug formulations carry specific FDA regulatory considerations. Consumers should note this distinction when comparing Hims chewable products to standard FDA-approved generics available at retail pharmacies for $10, $20 per 30-dose supply.

Hair Loss Products

Finasteride oral tablets (1 mg) are a commodity generic. Retail GoodRx pricing for 30 tablets of finasteride 1 mg is approximately $10, $15/month at major pharmacy chains. Hims charges $30, $45/month for the same finasteride, bundled with a telehealth consultation. The consultation has genuine value for first-time users requiring a prescription, but the ongoing subscription premium is substantial once a diagnosis is established.

Minoxidil topical solution or foam (5%) is available over the counter for $8, $12/month at retail. Hims offers minoxidil as part of bundles starting at $25, $40/month, often combined with finasteride. The bundling makes individual product cost comparisons difficult, which is likely intentional.

Mental Health and Primary Care

Hims offers sertraline, escitalopram, and buspirone through its mental health platform, typically for $25, $49/month including the prescriber visit. Generic sertraline is available for $4, $10/month via GoodRx at retail pharmacies. The Hims premium here is entirely attributed to the telehealth visit cost, which may be appropriate for initial diagnosis but represents a recurring cost for maintenance patients who could transfer their prescription to a retail pharmacy.

Weight Loss (GLP-1 / Compounded Semaglutide)

This is Hims's highest-growth and most contested product line. Compounded semaglutide at Hims launched in 2023 at $199/month, rose to $249, $299/month by mid-2024, and some users report being quoted $349/month on current plans. By comparison, STEP-1 (N=1,961) showed that semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo, establishing the clinical case for GLP-1 therapy. Whether compounded semaglutide delivers equivalent pharmacokinetics to the approved Wegovy formulation is not established in published trials.

The FDA issued a guidance document in October 2023 clarifying that compounded drugs are not FDA-approved and have not been proven safe or effective. That guidance is available on FDA.gov. As FDA enforcement on compounded semaglutide tightens in 2025, Hims's cost advantage in this category will narrow or disappear.

Complaint Data and Regulatory Record

Understanding the complaint field is essential for anyone evaluating Hims as a healthcare provider, not just a subscription service.

Better Business Bureau Complaints

The BBB profile for Hims & Hers as of Q4 2024 shows more than 1,900 complaints filed, earning a B rating (not the top A or A+ grade). The predominant complaint categories are:

1. Billing and collection issues (unauthorized recurring charges after cancellation)
2. Problems with product or service (prescription not received, incorrect formulation shipped)
3. Delivery issues

A B BBB rating does not indicate fraud, but the volume of billing complaints is above average for a subscription healthcare company. The BBB is not a regulatory body; its data functions as a consumer signal.

State Medical Board and Prescribing Practice Concerns

Multiple state medical boards have examined direct-to-consumer telehealth prescribing practices broadly, including models like Hims's. The core concern is asynchronous prescribing: a patient fills out a questionnaire, and a provider prescribes without a real-time visit. The Federation of State Medical Boards published a telemedicine policy framework in 2020 noting that "the standard of care is not diminished because the visit is conducted via telemedicine" and that a valid patient-physician relationship must exist before prescribing.

California, New York, and Texas have at different times issued guidance limiting or requiring synchronous visits for controlled substances and certain medications. Hims does not prescribe Schedule II, IV controlled substances for most indications, limiting direct DEA exposure, but the prescribing model continues to attract scrutiny.

LegitScript Certification Status

LegitScript is the primary third-party verification service for online pharmacies and telehealth companies. As of the date of this article, Hims does not hold LegitScript certification as a compliant online pharmacy. LegitScript's public database allows consumers to check certification status directly.

This does not make Hims illegal. Hims works with PCAB-accredited compounding pharmacies and state-licensed dispensing pharmacies. The absence of LegitScript certification does mean Hims has not completed that specific third-party verification process, which is worth knowing when comparing providers.

Is Hims Legit?

This is the most common search question about the company. The answer requires separating several distinct questions.

Is Hims a Real, Licensed Business?

Yes. Hims & Hers Health, Inc. Is a publicly traded company (NYSE: HIMS) subject to SEC reporting requirements. It operates through a network of licensed medical providers and state-licensed pharmacies. The company files annual 10-K reports and quarterly 10-Q reports with full financial disclosure. Patients receive real medications from real licensed pharmacies.

Are the Medications Real and Safe?

For FDA-approved generics (sildenafil, finasteride, tadalafil, sertraline), yes. These are the same molecules available at any retail pharmacy, often sourced from the same generic manufacturers. The compounded products carry more uncertainty. The FDA explicitly states that compounded drugs "lack FDA approval" and the agency "has not reviewed them for safety, effectiveness, or quality."

Is the Pricing Model Transparent?

This is where legitimate criticism applies. Hims advertises the lowest possible tier price ("starting at $X") in large font, with the conditions for that price (multi-month prepay, auto-renew enrollment) in smaller disclosure text. The FTC has broad authority over deceptive pricing practices, and subscription cancellation difficulty is an established consumer protection concern. The FTC's "Click-to-Cancel" rule, published in 2024, directly targets subscription services that make cancellation harder than sign-up.

The framework below summarizes how to evaluate Hims versus retail pharmacy or a local telehealth provider across four dimensions: cost, convenience, clinical oversight, and regulatory standing.

| Dimension | Hims | Retail Pharmacy + Local MD | Other Telehealth (e.g., Ro, Done) | |---|---|---|---| | Entry price (ED sildenafil) | $1, $5/dose | $0.30, $0.50/dose (GoodRx) | $2, $6/dose | | Ongoing subscription required | Yes, 3-month prepay for best rate | No | Varies | | LegitScript certified | No | N/A (retail) | Varies by provider | | Compounded GLP-1 offered | Yes (regulatory uncertainty) | No | Yes (same uncertainty) | | BBB complaint volume | High (1,900+) | N/A | Moderate | | FDA-approved formulations only | Mostly, except chewables and compounded GLP-1 | Yes | Mostly |

Price Trajectory: What to Expect Through 2026

Three forces are likely to push Hims pricing higher or force product exits in the next 12 to 24 months.

FDA Enforcement on Compounded Semaglutide

The FDA has stated it will take action against compounding pharmacies producing semaglutide after the shortage resolution. The FDA's February 2024 update on the semaglutide shortage and compounding status is the governing document here. If Hims loses the ability to offer compounded semaglutide, its $199, $299/month GLP-1 product disappears. The only alternatives for patients would be brand-name Wegovy at $900+/month (before insurance) or a different GLP-1 that remains in shortage status.

Subscription Regulation and the FTC Click-to-Cancel Rule

The FTC's Click-to-Cancel rule requires that canceling a subscription be as easy as signing up, effective 2025. Hims's current cancellation process involves multiple confirmation screens and retention offers. Compliance costs and potential refund liability from this rule will add operational expense that tends to flow through to pricing.

Generic Competition in Core Categories

Paradoxically, commodity pricing pressure may keep ED and hair loss medication costs from rising further. Sildenafil generics are now $0.30, $0.50/dose at retail with GoodRx. If Hims raises prices significantly above current levels, price-sensitive subscribers will switch to retail. This creates a ceiling for ED and hair product pricing but does not constrain the GLP-1 or compounded peptide categories where retail alternatives are limited.

How Hims Pricing Compares to Clinical Guidelines

The Endocrine Society's 2018 clinical practice guidelines on testosterone therapy recommend that treatment be initiated only after laboratory confirmation of hypogonadism (total testosterone <300 ng/dL on two morning samples). That guideline is available through the Endocrine Society's official publications. Hims does not prominently offer testosterone therapy as of 2024, but its model of questionnaire-based prescribing raises the same access-versus-oversight tension for any hormonal product.

The American Urological Association's 2018 guidelines on erectile dysfunction state that "a thorough medical, sexual, and psychosocial history" is required before ED treatment, which in practice requires more than a questionnaire. The full guideline is published through the AUA's education portal. Hims's asynchronous model may not satisfy this standard for all patients, particularly those with cardiovascular risk factors for whom PDE5 inhibitors carry contraindication risk.

The American Association of Clinical Endocrinology (AACE) 2023 guidelines for obesity management support GLP-1 receptor agonist use in patients with BMI >30 or BMI >27 with at least one weight-related comorbidity. AACE guidelines are accessible through their official publications. Hims's GLP-1 prescribing screening process does not always include the laboratory and cardiovascular workup that these guidelines recommend before initiation.

What Actual Patients Pay Versus Advertised Prices

The gap between advertised "starting at" prices and actual monthly spend is worth quantifying. Based on Hims's own publicly visible pricing tiers and consumer complaint patterns:

• Advertised sildenafil: "$1/dose" requires purchasing 30 doses (3-month prepay at $30 total for that tier, with auto-renew)
• Actual average reported spend for ED: $50, $80/month when including consultation fees on first visit and mid-tier dosing
• Advertised finasteride: "$20/month" on some promotions
• Actual average reported spend for hair loss treatment: $35, $60/month including minoxidil bundle

The "starting at" framing is technically accurate but functionally misleading for most users, who end up on higher-cost tiers within the first two billing cycles. This is consistent with the subscription model optimization common in SaaS businesses, applied here to prescription medication.

The FTC's 2022 report on dark patterns in subscription services specifically identifies "drip pricing" (advertising a low entry price while adding fees at checkout or auto-upgrading tiers) as a problematic practice. Whether Hims's pricing presentation meets the legal threshold for deceptive practice has not been adjudicated, but the pattern is recognizable.